Seeking efficiency in executive compensation benchmarking?

Unlock Efficiency in Executive Compensation Benchmarking with CompAnalyst Executive

CompAnalyst Executive

The charts on this page feature a breakdown of the total annual pay for the top executives at BLACK DIAMOND THERAPEUTICS as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. BLACK DIAMOND THERAPEUTICS income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. BLACK DIAMOND THERAPEUTICS annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
David M. Epstein Ph.D.
Former President and Chief Executive Officer
Total Cash $412,300 Equity $1,049,520 Other $557,386 Total Compensation $2,019,206
Mark A. Velleca M.D., Ph.D.
President and Chief Executive Officer
Total Cash $294,000 Equity $2,591,404 Other $63,950 Total Compensation $2,949,354
Fang Ni Pharm.D.
Chief Business Officer and Interim Chief Financial Officer
Total Cash $640,226 Equity $823,542 Other $25,758 Total Compensation $1,489,526
Sergey Yurasov M.D., Ph.D.
Chief Medical Officer
Total Cash $693,315 Equity $514,760 Other $25,609 Total Compensation $1,233,684
For its 2021 fiscal year, BLACK DIAMOND THERAPEUTICS, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Alexander Mayweg, Ph.D. Total Cash $155,216
Ali Behbahani Total Cash $172,716
Bradley Bolzon, Ph.D. Total Cash $155,216
Garry E. Menzel, Ph.D. Total Cash $397,516
Kapil Dhingra, M.B.B.S. Total Cash $734,243
Mark Velleca, M.D., Ph.D. Total Cash $203,845
Rajeev Shah Total Cash $162,716
Robert A. Ingram Total Cash $188,716
Samarth Kulkarni Total Cash $382,516

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.